Solid State Boost at Onyx
News Dec 10, 2013
Onyx Scientific has unveiled a huge increase in demand for its solid-state chemistry services versus last year.
The contract research and manufacturing organization has reported a 45% uplift in solid formulation related revenues, which is being driven by early stage drug development projects.
The company’s close alliance with Molecular Profiles, announced last year, has also led to more work as a result of increasing activity in the biotechnology and early stage clinical sector.
Denise Bowser, commercial director at Onyx Scientific, said: “Over the past few years, we have proudly become a real specialist in solid-state chemistry focused on providing detailed investigation to cut lead times for clients and ensure processes are scalable.
“As many drugs are formulated in solid dosage form, the need to understand, control and characterize the individual forms of a substance, in particular the polymorphic form, is vital. This is why we feel we have seen such an increased demand.”
In 2013, the company has worked with pharmaceutical and biotech clients across the globe assisting with integrated chemistry, process development and custom synthesis projects.
With MHRA and FDA facilities in the UK and India, Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.
Its UK-based labs deal with complex chemistry to deliver early stage programs and is then able to scale-up, tech transfer and increase project efficiency using its commercial manufacturing sites in India.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE